First Global Phase 3 Trial Showing Substantial Survival Advantage Over Chemotherapy, for Patients With Progression On or After Platinum-Based Chemotherapy ...

The FDA granted approval for the use of Skytrofa (lonapegsomatropin) in September 2021 for the treatment of pediatric ...

David Spigel, MD, discusses the significant benefits of durvalumab as consolidation therapy following standard ...

AstraZeneca (AZ) has announced that its Imfinzi (durvalumab)-based perioperative regimen has been approved by the European ...

AstraZeneca‘s IMFINZI® (durvalumab) has gained FDA approval for use in adult patients with muscle-invasive bladder cancer ...

EU approves AstraZeneca’s Imfinzi-in combo with chemotherapy to treat patients with resectable non-small cell lung cancer ...

The European Commission has approved a new regimen from AstraZeneca, which combines the company’s durvalumab with ...

欧盟委员会的决定基于AEGEAN III期临床试验结果，该试验显示与单独使用新辅助化疗相比，疾病复发、进展或死亡风险降低了32%。试验结果已发表在《新英格兰医学杂志》上。这一进展进一步巩固了阿斯利康的强劲表现，该公司报告在过去十二个月内收入同比增长18%，达到541亿美元。

Cambridge: AstraZeneca has announced that the Company's Imfinzi (durvalumab) in combination with chemotherapy has been ...

UK pharma major AstraZeneca (LSE: AZN) today reported extended approvals in Europe for two of its cancer drugs: Imfinzi ...

Approval based on AEGEAN Phase III trial results which showed a 32% reduction in the risk of recurrence, progression or death vs. neoadjuvant chemotherapy alone ...

Matt Galsky, MD, delved into the recent approval of a perioperative durvalumab regimen in muscle-invasive bladder cancer.